Literature DB >> 25891666

Treatment of Paraneoplastic Hyperammonemia in Fibrolamellar Hepatocellular Carcinoma With Oral Sodium Phenylbutyrate.

Hans Ulrich Bender1, Michael Staudigl2, Irene Schmid3, Monika Führer4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25891666     DOI： 10.1016/j.jpainsymman.2015.03.007

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN： 0885-3924            Impact factor:   3.612


× No keyword cloud information.
  5 in total

1.  Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review.

Authors:  Janice Cho; Joy C Y Chen; Jonas Paludo; Erin E Conboy; Brendan C Lanpher; Steven R Alberts; Thorvardur R Halfdanarson
Journal:  J Gastrointest Oncol       Date:  2019-06

2.  Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.

Authors:  Claudia I Chapuy; Inderneel Sahai; Rohit Sharma; Andrew X Zhu; Olga N Kozyreva
Journal:  Oncologist       Date:  2016-03-14

3.  A Proposed Physiopathological Pathway to Hyperammonemic Encephalopathy in a Non-Cirrhotic Patient with Fibrolamellar Hepatocellular Carcinoma without Ornithine Transcarbamylase (OTC) Mutation.

Authors:  Rodrigo C Surjan; Elizabeth S Dos Santos; Tiago Basseres; Fabio F Makdissi; Marcel A Machado
Journal:  Am J Case Rep       Date:  2017-03-08

4.  Hyperammonemic encephalopathy: An unusual presentation of fibrolamellar hepatocellular carcinoma.

Authors:  Nimish Thakral; Douglas A Simonetto
Journal:  Clin Mol Hepatol       Date:  2019-08-16

5.  Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience.

Authors:  Anastasia Lemekhova; Daniel Hornuss; Georgios Polychronidis; Philipp Mayer; Christian Rupp; Thomas Longerich; Karl-Heinz Weiss; Markus Büchler; Arianeb Mehrabi; Katrin Hoffmann
Journal:  World J Surg Oncol       Date:  2020-05-12       Impact factor: 2.754
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.